Search research articles
Contact Us
Filters
Showing results (51-60 of 59) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 59 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 19, 2023
Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial
Yiwen Ling, Li Xuan, Na Xu, et al.
Blood Cancer Journal
|
December 7, 2021
Dynamic assessment of measurable residual disease in favorable-risk acute myeloid leukemia in first remission, treatment, and outcomes
Sijian Yu, Tong Lin, Danian Nie, et al.
Journal of Hematology & Oncology
|
April 29, 2023
Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
Hua Jin, Yu Zhang, Sijian Yu, et al.
British Journal of Haematology
|
May 21, 2025
Venetoclax plus azacitidine with or without homoharringtonine followed by allogeneic haematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukaemia: A multicentre cohort study
Yiling Ye, Xinyu Liu, Huajuan Dai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 12, 2024
Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multicenter Cohort Study
Guopan Yu, Yu Zhang, Sijian Yu, et al.
JAMA Network Open
|
July 7, 2021
Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and Outcomes
Sijian Yu, Zhiping Fan, Liping Ma, et al.
Journal of Internal Medicine
|
October 29, 2023
Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory/relapsed acute myeloid leukemia with FLT3-ITD: A multicenter phase 2 study
Sijian Yu, Yu Zhang, Guopan Yu, et al.
Experimental Hematology & Oncology
|
July 7, 2026
Autologous transplant versus matched sibling donor transplant in intermediate-risk AML in CR1 with no detectable MRD: a biological assignment comparative study
Sijian Yu, Hui Liu, Weihua Zhao, et al.
Leukemia
|
May 28, 2025
High-dose cytarabine with idarubicin consolidation for acute myeloid leukemia in first complete remission: a randomized controlled trial
Yu Zhang, Zinan Feng, Jing Du, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 59) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 59 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 19, 2023
Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial
Yiwen Ling, Li Xuan, Na Xu, et al.
Blood Cancer Journal
|
December 7, 2021
Dynamic assessment of measurable residual disease in favorable-risk acute myeloid leukemia in first remission, treatment, and outcomes
Sijian Yu, Tong Lin, Danian Nie, et al.
Journal of Hematology & Oncology
|
April 29, 2023
Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
Hua Jin, Yu Zhang, Sijian Yu, et al.
British Journal of Haematology
|
May 21, 2025
Venetoclax plus azacitidine with or without homoharringtonine followed by allogeneic haematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukaemia: A multicentre cohort study
Yiling Ye, Xinyu Liu, Huajuan Dai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 12, 2024
Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multicenter Cohort Study
Guopan Yu, Yu Zhang, Sijian Yu, et al.
JAMA Network Open
|
July 7, 2021
Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and Outcomes
Sijian Yu, Zhiping Fan, Liping Ma, et al.
Journal of Internal Medicine
|
October 29, 2023
Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory/relapsed acute myeloid leukemia with FLT3-ITD: A multicenter phase 2 study
Sijian Yu, Yu Zhang, Guopan Yu, et al.
Experimental Hematology & Oncology
|
July 7, 2026
Autologous transplant versus matched sibling donor transplant in intermediate-risk AML in CR1 with no detectable MRD: a biological assignment comparative study
Sijian Yu, Hui Liu, Weihua Zhao, et al.
Leukemia
|
May 28, 2025
High-dose cytarabine with idarubicin consolidation for acute myeloid leukemia in first complete remission: a randomized controlled trial
Yu Zhang, Zinan Feng, Jing Du, et al.
Page
of 6